Skip to main content
P

Panion & BF Biotech Inc. — Investor Relations & Filings

Ticker · 1760 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Filings indexed 1,543 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country TW Taiwan
Listing TW 1760

About Panion & BF Biotech Inc.

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
114年年報及股東會資料 — 2025_1760_20260525FE4.pdf
Regulatory Filings
2026-05-06 Chinese
114年年報及股東會資料 — 2025_1760_20260525F04.pdf
Regulatory Filings
2026-05-06 Chinese
114年年報及股東會資料 — 2026_1760_20260525F17.pdf
Regulatory Filings
2026-05-06 Chinese
公告本公司115年第一季財務報告董事會預計召開日期 為115年5月12日
Regulatory Filings
2026-05-06 Chinese
本公司腎病新藥拿百磷獲得中國核准上市
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement (public disclosure on a material event) about the company’s new drug Nephoxil receiving China NMPA approval. It is not a full financial report, earnings release, board change, dividend notice, or other specific category. It is a general regulatory filing of material news, so it falls under the fallback category 'Regulatory Filings' (RNS).
2026-04-27 Chinese
115年年報及股東會資料 — 2026_1760_20260525FE2.pdf
AGM Information Classification · 1% confidence The document is explicitly titled “2026 Annual General Meeting of Shareholders Handbook” and contains the meeting agenda, procedures, proposals, appendices including business reports, audit reviews, and financial statements prepared for the AGM. It is clearly materials distributed for the Annual General Meeting rather than the annual report itself or any other announcement. Therefore, this is AGM Information.
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.